Why did Narayana Hrudayalaya (NH) stock move recently?

On 7/27/2026, Narayana Hrudayalaya moved +4.7% — No clear company-specific catalyst identified in filings or today's coverage; the stock rose with broader market or sector sentiment. This is MarketChacha's decoded reason from filings and credible news; it is education, not buy/sell advice.

Is Narayana Hrudayalaya (NH) overvalued or fairly valued?

MarketChacha shows Narayana Hrudayalaya's valuation in context — a forward P/E of about 26.5, a price-to-book of about 8.3 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

What is Narayana Hrudayalaya's revenue?

Narayana Hrudayalaya reported revenue of ₹7,896 Cr for FY2026, with net profit of ₹806 Cr, per official filings.

What is the share price of Narayana Hrudayalaya (NH)?

Narayana Hrudayalaya last traded at ₹1,858.50 (-3.3% on the day), as of 9/4/2026 — a delayed quote shown for education, not investment advice.

Narayana Hrudayalaya

NH · NSE · Healthcare · India

Snapshot

TickerNH

ExchangeNSE

SectorHealthcare

IndustryMedical Care Facilities

CountryIndia

Employees11,234

HeadquartersBengaluru, India

Websitewww.narayanahealth.org

Filings tracked8

About Narayana Hrudayalaya

Narayana Hrudayalaya Limited provides medical and healthcare services in India, the United Kingdom, and the Cayman Islands. It operates through the Medical and Healthcare Related Services; and Others segments. The company offers oncology, anesthesiology, audiology, blood bank, breast oncology, oncoplastic surgery, cardiac surgery, cardiology, clinical genetics, clinical immunology, clinical nutrition and dietetics, clinical psychology, congenital adult heart disease, cosmetology, cranio-maxillofacial surgery, critical care medicine, dental, dermatology, diabetology, ENT, emergency medicine, endocrinology, family medicine, general and GI surgery, general medicine and surgery, geriatric medicine, gynecology, hematology, headache and facial pain management, transplant, infectious diseases, neurology, radiology, hepatobiliary surgery, gastroenterology, minimal access GI and bariatric surgery, neonatology, nephrology, neuro-otology, neuro-rehabilitation, neurosurgery and spine surgery, and nuclear medicine services. It also provides ophthalmology, orthopedics and joint replacement, pain management and palliative care, pathology, perinatology and fetal intervention, physical medicine and rehabilitation, physiotherapy and physical rehabilitation, plastic surgery, psychiatry, pulmonology, reproductive medicine, rheumatology, renal science, speech and swallow rehabilitation, spine surgery, thoracic and vascular surgery, uro oncology, urology, and other services. In addition, the company acquires, owns, and operates hospitals, clinics, health centers, diagnostic centers, and nursing homes. Further, it provides health insurance, consultancy services in the field of healthcare and hospitals, and IT services related to healthcare. Additionally, the company engages in investment activities; and develops software related to the healthcare industry. The company was incorporated in 2000 and is headquartered in Bengaluru, India.

Who owns it

Promoters67.2%
Institutions12.8%
Public & other19.9%

80 institutional holders

Ownership breakdown from public market data. Promoter pledge is not included here — that comes from exchange shareholding filings.

Forensic scorecard

Margin has compressed by about 3.2 points over the period — profitability is trending down.

Net margin trend13.4% → 10.2%

Margin has compressed by about 3.2 points over the period — profitability is trending down.

Growth qualityrev 20% · PAT 10%

Profit growth is broadly tracking revenue growth — the earnings trend looks operational rather than one-off.

Computed by MarketChacha from reported figures (Yahoo Finance). Education, not a rating or recommendation.

What's expected next

Next quarter

Rev ₹2,782 Cr · EPS 13.90

Est. earnings growth +64.6%

Next fiscal year

Rev ₹12,113 Cr · EPS 70.08

Est. earnings growth +28.1%

Analyst consensus estimates — not the company's own guidance.

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Financials at a glance

Source: Yahoo Finance

Annual

Quarterly · last 5

Revenue (FY2026)

₹7,896 Cr

Net margin

10.2%

Revenue CAGR (3y)

+20.4%

Profit CAGR (3y)

+9.9%

Net profit (FY2026)

₹806 Cr

Ask MarketChacha about NH

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

Why it moved

Jul 27, 2026
No clear company-specific catalyst identified in filings or today's coverage; the stock rose with broader market or sector sentiment.
· confidence: low

Daily moves with the verified reason behind them. Education only — not investment advice.

Financials

Yearly

Period	Revenue	Net profit	Net margin
FY2026	₹7,896 Cr	₹806 Cr	10.2%
FY2025	₹5,617 Cr	₹790 Cr	14.1%
FY2024	₹5,018 Cr	₹789 Cr	15.7%
FY2023	₹4,525 Cr	₹606 Cr	13.4%

Quarterly

Period	Revenue	Net profit	Net margin
Q1 FY27	₹2,684 Cr	₹207 Cr	7.7%
Q4 FY26	₹2,594 Cr	₹224 Cr	8.6%
Q3 FY26	₹2,151 Cr	₹127 Cr	5.9%
Q2 FY26	₹1,644 Cr	₹258 Cr	15.7%
Q1 FY26	₹1,507 Cr	₹197 Cr	13.0%

Figures as reported, in ₹ (crore). Source: Yahoo Finance.

Filings & announcements

2026

Earnings Call Transcript
Transcript of the Earnings Call of the company for the quarter ended June 30, 2026.
BSE8/10/2026
Investor Presentation
Investor presentation for the quarter ended June 30, 2026.
BSE7/31/2026
Press Release / Media Release
Press release for the quarter ended June 30, 2026.
BSE7/31/2026
Unaudited Financial Results (Standalone And Consolidated) For The Quarter Ended June 30, 2026
unaudited financial results (standalone and consolidated) for the quarter ended June 30, 2026
BSE7/31/2026
Board Meeting Outcome for Outcome Of The Board Meeting For Unaudited Financial Results (Standalone And Consolidated) For The Quarter Ended June 30, 2026
Outcome of the Board meeting for unaudited Financial Results (Standalone And Consolidated) For The Quarter ended June 30, 2026
BSE7/31/2026
Business Responsibility and Sustainability Reporting (BRSR)
BRSR for F.Y. 2025-26
BSE7/23/2026
Reg. 34 (1) Annual Report.
Annual Report for FY 2025-26
BSE7/23/2026
Notice Of The 26Th Annual General Meeting (''''''''AGM'''''''') Of The Company For F.Y. 2025-26
Notice of the 26th Annual General Meeting of the company for FY 2025-26
BSE7/23/2026material

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed market data) are delayed and shown for reference only. Verify with the linked sources before acting.